Acadia Healthcare Credit Rating & NNN Cap Rate Analysis

Acadia Healthcare Business Overview & NNN Investment Profile

Acadia Healthcare is the largest provider of behavioral healthcare services in the United States, operating 277 facilities with more than 12,500 licensed beds across 40 states and Puerto Rico. The company’s service lines span four categories: acute inpatient psychiatric facilities (59 hospitals treating high-acuity conditions), specialty treatment facilities for substance use disorders, comprehensive treatment centers (174 CTCs across 33 states treating over 74,000 patients daily for opioid use disorder), and residential treatment centers. Acadia generated $3.31 billion in revenue in fiscal year 2025, with acute inpatient psychiatric services contributing the largest share.

For NNN investors, Acadia represents an important segment of the healthcare real estate market that is fundamentally different from traditional medical office or hospital properties. Behavioral health and addiction treatment facilities are purpose-built environments that require specialized construction, licensing, and accreditation. These facilities are difficult to repurpose for other uses, which means NNN investors are more reliant on Acadia’s creditworthiness and operational stability than on the re-tenanting potential of the underlying real estate. Acadia’s aggressive expansion strategy, adding 1,089 licensed beds in 2025 alone including 778 from newly constructed facilities, demonstrates the company’s commitment to growth but also creates significant capital expenditure pressure.

Why Acadia Healthcare Matters for NNN Investors

The behavioral health sector has structural tailwinds that few other healthcare segments can match. The United States faces a well-documented mental health crisis, with demand for psychiatric and addiction treatment services far outstripping available capacity in most markets. Acadia’s scale gives it a dominant position in addressing this gap: with 277 facilities and 21 joint venture partnerships for an additional 22 hospitals (13 operational, 9 in development), Acadia is building out the national infrastructure for behavioral healthcare in a way that no competitor can match at the same pace.

The joint venture model is particularly relevant for NNN investors because it means Acadia is partnering with established health systems to develop new behavioral health hospitals. These partnerships often involve sale-leaseback structures where the property is owned by an investor or the health system partner and leased to Acadia on a long-term NNN basis. Lease structures on Acadia properties typically feature 10 to 20 year initial terms with annual escalations and corporate guarantees from the publicly traded parent entity. However, the B+/B1 credit rating means investors should expect wider cap rates to compensate for the elevated default risk relative to investment-grade health system tenants.

Cap Rate Analysis & Pricing for Acadia Healthcare NNN Properties

Acadia Healthcare NNN properties trade in the 7.00% to 8.50% cap rate range as of Q1 2026. The wide spread reflects the B+/B1 credit rating, the recent goodwill impairment, and uncertainty around Medicaid reimbursement policy. Newer purpose-built acute psychiatric hospitals with 15+ year remaining terms and health system joint venture partners may trade toward the tighter end, while older specialty treatment or residential facilities with shorter terms may approach 8.50% or beyond. The specialized nature of behavioral health facilities, which limits re-tenanting options, contributes to the wider cap rate range compared to general medical office NNN properties of similar credit quality.

Pricing for Acadia NNN properties ranges widely from $5 million for smaller CTCs and residential treatment centers to $30 million or more for large acute inpatient psychiatric hospitals. These properties attract specialized healthcare real estate investors who understand behavioral health operations and licensing requirements. Institutional buyers, including healthcare-focused REITs, participate in the larger transactions, while private investors may find opportunities in the smaller CTC and specialty treatment segments.